ストックスクリーナーアプリを入手
5.23
9.64%
0.46
前日終値:
$4.77
開ける：
$4.82
24時間の取引高:
1.92M
Relative Volume:
1.02
時価総額：
$741.84M
収益：
$288.95M
当期純損益:
$-119.03M
株価収益率:
-5.8079
EPS:
-0.9005
ネットキャッシュフロー:
$60.67M
1週間 パフォーマンス:
+15.20%
1か月 パフォーマンス:
-2.61%
6か月 パフォーマンス:
-39.47%
1年 パフォーマンス:
-16.32%
1日の値動き範囲:
$4.64
$5.25
1週間の範囲:
$4.38
$5.25
52週間の値動き範囲:
$4.275
$11.55
Maravai Lifesciences Holdings Inc Stock (MRVI) Company Profile
名前
Maravai Lifesciences Holdings Inc
セクター
電話
(858) 546-0004
住所
10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO
MRVI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRVI
Maravai Lifesciences Holdings Inc
|
5.23 | 741.84M | 288.95M | -119.03M | 60.67M | -0.9005 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Maravai Lifesciences Holdings Inc Stock (MRVI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-19 | 開始されました | Guggenheim | Neutral |
| 2024-12-05 | ダウングレード | Goldman | Neutral → Sell |
| 2024-11-14 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-08 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-08-28 | 開始されました | Wells Fargo | Overweight |
| 2024-08-13 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-04-10 | 開始されました | Craig Hallum | Buy |
| 2023-12-12 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-08-08 | ダウングレード | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-05-23 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-05-09 | ダウングレード | Goldman | Buy → Neutral |
| 2023-01-05 | ダウングレード | UBS | Buy → Neutral |
| 2022-12-14 | 開始されました | Deutsche Bank | Buy |
| 2022-12-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-11-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-08-25 | 開始されました | Credit Suisse | Outperform |
| 2021-08-05 | 再開されました | Credit Suisse | Outperform |
| 2020-12-16 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2020-12-15 | 開始されました | BofA Securities | Buy |
| 2020-12-15 | 開始されました | Credit Suisse | Outperform |
| 2020-12-15 | 開始されました | Goldman | Buy |
| 2020-12-15 | 開始されました | Jefferies | Buy |
| 2020-12-15 | 開始されました | Robert W. Baird | Outperform |
| 2020-12-15 | 開始されました | Stifel | Buy |
| 2020-12-15 | 開始されました | William Blair | Outperform |
| 2020-12-14 | 開始されました | UBS | Buy |
すべてを表示
Maravai Lifesciences Holdings Inc (MRVI) 最新ニュース
Maravai LifeSciences Holdings, Inc. (MRVI) Stock: An Under $5 Gem with Biggest Upside Potential - Yahoo Canada Finance
12 Stocks Under $5 With Biggest Upside Potential - Insider Monkey
Maravai LifeSciences (NASDAQ:MRVI) Shares Gap UpTime to Buy? - MarketBeat
Are Investors Undervaluing Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) By 43%? - Simply Wall St
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Shares Bought by Barclays PLC - Defense World
How the (MRVI) price action is used to our Advantage - Stock Traders Daily
Maravai LifeSciences Holdings (STU:MAR) Other Stockholders Equity : €0.0 Mil (As of Sep. 2024) - GuruFocus.com
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Rating of “Hold” by Analysts - Defense World
Maravai LifeSciences (NASDAQ:MRVI) Stock Price Down 15.7%Here's What Happened - MarketBeat
Stock Traders Buy High Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI) - MarketBeat
Maravai LifeSciences Sees Unusually High Options Volume (NASDAQ:MRVI) - Defense World
Maravai Lifesciences Holdings, Inc. Eliminates Andrew Burch as President, Nucleic Acid Production - Marketscreener.com
Maravai LifeSciences Holdings Projects 2024 Revenue Near Midpoint of Guidance - MarketWatch
Maravai LifeSciences Restructures Leadership Amid Revenue Update - TipRanks
Maravai LifeSciences projects FY revenue near mid-range guidance; shares fall - Investing.com Australia
Maravai LifeSciences Announces Preliminary Unaudited 2024 Revenue - The Manila Times
Maravai LifeSciences (MRVI) Announces In-Line Preliminary 2024 Revenue - StreetInsider.com
Maravai LifeSciences Expects 2024 Revenue to Hit Mid-Range of $255-265M Guidance - StockTitan
JPMorgan Chase & Co. Raises Position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - MarketBeat
JPMorgan Chase & Co. Has $33.66 Million Stock Holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Jane Street Group LLC Sells 201,787 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Shares Sold by Jane Street Group LLC - MarketBeat
Principal Financial Group Inc. Reduces Position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Principal Financial Group Inc. Has $2.93 Million Stake in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - MarketBeat
Franklin Resources Inc. Takes $600,000 Position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Shares Acquired by Barclays PLC - Defense World
Geode Capital Management LLC Raises Stock Holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - MarketBeat
Geode Capital Management LLC Grows Position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Maravai LifeSciences (NASDAQ:MRVI) Shares Gap DownHere's What Happened - MarketBeat
Investors Buy High Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI) - Defense World
State Street Corp Sells 16,338 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Objective long/short (MRVI) Report - Stock Traders Daily
Maravai Lifesciences initiated with a Neutral at Guggenheim - Yahoo Finance
MRVI Stock Drops 5% Amidst Biotech Sector Decline - GuruFocus.com
Guggenheim starts Maravai LifeSciences stock with neutral rating - Investing.com
Danaher, Cryoport, Sartorius win Buy at Guggenheim (DHR:NYSE) - Seeking Alpha
Guggenheim starts Maravai LifeSciences stock with neutral rating By Investing.com - Investing.com UK
Guggenheim Initiates Coverage on Maravai LifeSciences (NASDAQ:MRVI) - MarketBeat
Exploring December 2024's Undervalued Small Caps With Insider Action In US - Simply Wall St
Maravai LifeSciences reduces debt by $228 million - Investing.com Australia
Maravai LifeSciences reduces debt by $228 million By Investing.com - Investing.com South Africa
Maravai LifeSciences (NASDAQ:MRVI) Stock Price Down 4.8%Time to Sell? - MarketBeat
Maravai LifeSciences (NASDAQ:MRVI) Trading Up 3.8%Here's Why - MarketBeat
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Recommendation of “Hold” by Brokerages - Defense World
Maravai LifeSciences' SWOT analysis: stock outlook amid mRNA manufacturing expansion - Investing.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.71 Million Position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
The Manufacturers Life Insurance Company Has $490,000 Stake in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Traders Purchase Large Volume of Put Options on Maravai LifeSciences (NASDAQ:MRVI) - MarketBeat
Charles Schwab Investment Management Inc. Has $7.87 Million Stock Position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Maravai LifeSciences' SWOT analysis: stock faces challenges amid growth potential - Investing.com Nigeria
Maravai Lifesciences Holdings Inc (MRVI) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):